Clinical Trial

VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization

Study acronym: RESOLUTION
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated March 12, 2025 (before its estimated July 20, 2025 completion). Its status may not reflect the trial's current state.
Summary
Venous thromboembolism (VTE) has a high prevalence in patients with multiple comorbidities undergoing complex surgical procedures. Sometimes, extended prophylaxis for VTE with KLMWH or direct oral anticoagulants (DOACs) is necessary. Currently, there is no consensus in the literature regarding the use of DOACs for extended VTE prophylaxis in patients undergoing lower limb revascularization (LLR). Objective: To evaluate the use of DOACs (already approved to reduce MACE and MALE) in VTE prophylaxis in patients undergoing LLR.
Trial Details
NCT Number NCT06873321
Lead Sponsor Science Valley Research Institute
Conditions Peripheral Arterial Disease, Venous Thormboembolism, Cardiovascular Diseases, Vascular Surgery Patient with PAD / Carotid Stenosis
Enrollment 100 participants
Start Date 2024-02-24
Primary Completion 2025-07-20 (estimated)
Study Completion 2025-07-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-12